Press release
The Neuroendocrine Tumor Research Symposium brings together researchers from around the world-fostering collaboration and leading-edge innovations in the treatment of this uncommon cancer.
BOSTON, M.A., November 6, 2024 - The 2024 Margie & Robert E. Petersen Neuroendocrine Tumor Research Symposium was held October 28-30 at The Hotel Commonwealth in Boston, Massachusetts. Organized by the Neuroendocrine Tumor Research Foundation (NETRF) the Symposium attracted over 120 researchers from around the world to discuss the latest advancements in neuroendocrine cancer research. The annual event plays a pivotal role in advancing scientific knowledge, promoting innovation and translating these studies into practical therapies for patients with this often-misdiagnosed disease.
"NETRF is proud of the strength of our scientific network which has resulted in 88 new collaborations, 22 clinical trials and projects, and 8 patents for new technology," says Elyse Gellerman, Chief Executive Officer for NETRF. "NETRF events like this enrich the scientific community… and even more importantly they result in trials, treatments and potential cures for neuroendocrine cancer."
Top Takeaways from Symposium Include:
1. Keynote and Distinguished Service Award Presentation: Dr. Ramesh Shivdasani from Dana-Farber Cancer Institute and Harvard Medical School delivered the keynote address, discussing recent breakthroughs in identifying the cell changes that lead to intestinal neuroendocrine tumors. He was also honored with the NETRF Distinguished Service Award for his invaluable contributions and dedicated service as a member and former Chair of the NETRF Board of Scientific Advisors.
2. Neuroendocrine Cancer Therapies & Resistance Mechanisms:
This session focused on new therapeutic strategies, including immunotherapy, in neuroendocrine cancer treatment.
a. Dr. Xianxin Hua discussed the potential of CAR T-cell therapy, now in clinical trials, for targeting neuroendocrine tumors.
b. Dr. Eleonora Pelle presented a novel bispecific T-cell engager immunotherapy targeting somatostatin receptors.
c. Dr. Minah Kim examined factors contributing to resistance against anti-angiogenic therapies in pancreatic NETs
3. Neuroendocrine Cancer Screens and Omics:
This session highlighted the use of genomic and molecular tools to improve the diagnosis and treatment of neuroendocrine neoplasms (NENs), which include neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs).
a. Dr. Aatur Singhi discussed how genomic profiling reveals critical diagnostic and prognostic markers for pancreatic neuroendocrine tumors.
b. Dr. Nicolas Alcala discussed better methods to classify lung neuroendocrine tumors and emerging diagnostic criteria.
c. Dr. Allison Stewart presented strategies to target drug-resistant cells in high-grade neuroendocrine carcinomas, which are especially prone to relapse.
The Margie and Robert E. Petersen Neuroendocrine Tumor Research Symposium is NETRF's premier event to create a collaborative environment which empowers researchers to exchange ideas and collectively work towards breakthroughs that have the potential to transform the landscape of NET research.
Neuroendocrine Tumor Research Foundation
31 St. James Avenue, Suite 365 - Boston, MA 02116 - netrf.org
Lori Dolnick, Public Relations - loridolnick@loridolnick.com
Elyse Gellerman, CEO-elyse.gellerman@netrf.org
About NETRF
The mission of the Neuroendocrine Tumor Research Foundation (NETRF) is to fund research to discover cures and more effective treatments for neuroendocrine cancers. NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support.
NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. Get Involved, Donate, Learn More: Visit www.NETRF.org for more.
"NETRF is proud of the strength of our scientific network which has resulted in 88 new collaborations, 22 clinical trials and projects, and 8 patents for new technology," says Elyse Gellerman, Chief Executive Officer for NETRF. "NETRF events like this enrich the scientific community… and even more importantly they result in trials, treatments and potential cures for neuroendocrine cancer."
Top Takeaways from Symposium Include:
1. Keynote and Distinguished Service Award Presentation: Dr. Ramesh Shivdasani from Dana-Farber Cancer Institute and Harvard Medical School delivered the keynote address, discussing recent breakthroughs in identifying the cell changes that lead to intestinal neuroendocrine tumors. He was also honored with the NETRF Distinguished Service Award for his invaluable contributions and dedicated service as a member and former Chair of the NETRF Board of Scientific Advisors.
2. Neuroendocrine Cancer Therapies & Resistance Mechanisms:
This session focused on new therapeutic strategies, including immunotherapy, in neuroendocrine cancer treatment.
a. Dr. Xianxin Hua discussed the potential of CAR T-cell therapy, now in clinical trials, for targeting neuroendocrine tumors.
b. Dr. Eleonora Pelle presented a novel bispecific T-cell engager immunotherapy targeting somatostatin receptors.
c. Dr. Minah Kim examined factors contributing to resistance against anti-angiogenic therapies in pancreatic NETs
3. Neuroendocrine Cancer Screens and Omics:
This session highlighted the use of genomic and molecular tools to improve the diagnosis and treatment of neuroendocrine neoplasms (NENs), which include neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs).
a. Dr. Aatur Singhi discussed how genomic profiling reveals critical diagnostic and prognostic markers for pancreatic neuroendocrine tumors.
b. Dr. Nicolas Alcala discussed better methods to classify lung neuroendocrine tumors and emerging diagnostic criteria.
c. Dr. Allison Stewart presented strategies to target drug-resistant cells in high-grade neuroendocrine carcinomas, which are especially prone to relapse.
The Margie and Robert E. Petersen Neuroendocrine Tumor Research Symposium is NETRF's premier event to create a collaborative environment which empowers researchers to exchange ideas and collectively work towards breakthroughs that have the potential to transform the landscape of NET research.
Neuroendocrine Tumor Research Foundation
31 St. James Avenue, Suite 365 - Boston, MA 02116 - netrf.org
Lori Dolnick, Public Relations - loridolnick@loridolnick.com
Elyse Gellerman, CEO-elyse.gellerman@netrf.org
About NETRF
The mission of the Neuroendocrine Tumor Research Foundation (NETRF) is to fund research to discover cures and more effective treatments for neuroendocrine cancers. NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support.
NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. Get Involved, Donate, Learn More: Visit www.NETRF.org for more.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
